Clinical Trial Update: Safely Change From Bosentan to Ambrisentan in Pulmonary Hypertension [Phase 4]

View source ↗

Summary

Phase 4 trial update examining the safety of switching patients from bosentan to ambrisentan in pulmonary arterial hypertension; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Arterial Hypertension

Drugs mentioned

• LETAIRIS (ambrisentan)
• TRACLEER (bosentan)

Snippet

Sponsor: University of Alabama at Birmingham | Conditions: Pulmonary Arterial Hypertension | Phase 4 | Status: COMPLETED | Results posted: 2014-08-11